BR112016026814A8 - 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica - Google Patents
2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêuticaInfo
- Publication number
- BR112016026814A8 BR112016026814A8 BR112016026814A BR112016026814A BR112016026814A8 BR 112016026814 A8 BR112016026814 A8 BR 112016026814A8 BR 112016026814 A BR112016026814 A BR 112016026814A BR 112016026814 A BR112016026814 A BR 112016026814A BR 112016026814 A8 BR112016026814 A8 BR 112016026814A8
- Authority
- BR
- Brazil
- Prior art keywords
- thiadiazines
- trifluoroethyl
- pharmaceutical composition
- preparation process
- present
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- KJHPOHPHXKIEEH-UHFFFAOYSA-N 4-(2,2,2-trifluoroethyl)-2H-thiadiazine Chemical class FC(CC1=NNSC=C1)(F)F KJHPOHPHXKIEEH-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14181123 | 2014-08-15 | ||
| PCT/EP2015/068506 WO2016023927A1 (en) | 2014-08-15 | 2015-08-12 | 2,2,2-trifluoroethyl-thiadiazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016026814A2 BR112016026814A2 (pt) | 2017-08-15 |
| BR112016026814A8 true BR112016026814A8 (pt) | 2021-07-20 |
Family
ID=51302940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016026814A BR112016026814A8 (pt) | 2014-08-15 | 2015-08-12 | 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9896438B2 (https=) |
| EP (1) | EP3180330B1 (https=) |
| JP (1) | JP6543697B2 (https=) |
| KR (1) | KR20170043581A (https=) |
| CN (1) | CN106459006B (https=) |
| BR (1) | BR112016026814A8 (https=) |
| CA (1) | CA2952160A1 (https=) |
| MX (1) | MX375329B (https=) |
| RU (1) | RU2692102C2 (https=) |
| WO (1) | WO2016023927A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109180672A (zh) * | 2018-09-29 | 2019-01-11 | 广东东阳光药业有限公司 | 亚氨基噻二嗪二氧化物衍生物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19500558A1 (de) * | 1995-01-11 | 1996-07-18 | Merck Patent Gmbh | 3-Alkoxycarbonyl-thiadiazinone |
| EP2485590B1 (en) * | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2014150331A1 (en) * | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use |
| US9428476B2 (en) * | 2013-03-15 | 2016-08-30 | Merck Sharp & Dohme Corp. | S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use |
| CN105683199B (zh) * | 2013-12-20 | 2018-06-26 | 豪夫迈·罗氏有限公司 | 5-芳基-1-亚氨基-1-氧代-[1，2，4]噻二嗪 |
-
2015
- 2015-08-12 WO PCT/EP2015/068506 patent/WO2016023927A1/en not_active Ceased
- 2015-08-12 US US15/502,044 patent/US9896438B2/en not_active Expired - Fee Related
- 2015-08-12 MX MX2016016061A patent/MX375329B/es active IP Right Grant
- 2015-08-12 JP JP2017506993A patent/JP6543697B2/ja not_active Expired - Fee Related
- 2015-08-12 KR KR1020177006946A patent/KR20170043581A/ko not_active Ceased
- 2015-08-12 EP EP15748252.2A patent/EP3180330B1/en not_active Not-in-force
- 2015-08-12 CA CA2952160A patent/CA2952160A1/en not_active Abandoned
- 2015-08-12 CN CN201580032183.8A patent/CN106459006B/zh not_active Expired - Fee Related
- 2015-08-12 RU RU2017107495A patent/RU2692102C2/ru active
- 2015-08-12 BR BR112016026814A patent/BR112016026814A8/pt active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| CN106459006A (zh) | 2017-02-22 |
| BR112016026814A2 (pt) | 2017-08-15 |
| JP6543697B2 (ja) | 2019-07-10 |
| US9896438B2 (en) | 2018-02-20 |
| WO2016023927A1 (en) | 2016-02-18 |
| RU2017107495A (ru) | 2018-09-17 |
| RU2017107495A3 (https=) | 2019-02-25 |
| CA2952160A1 (en) | 2016-02-18 |
| US20170226091A1 (en) | 2017-08-10 |
| MX2016016061A (es) | 2017-03-10 |
| MX375329B (es) | 2025-03-06 |
| CN106459006B (zh) | 2020-02-11 |
| EP3180330B1 (en) | 2021-03-03 |
| KR20170043581A (ko) | 2017-04-21 |
| JP2017524006A (ja) | 2017-08-24 |
| EP3180330A1 (en) | 2017-06-21 |
| RU2692102C2 (ru) | 2019-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
| BR112014015630A8 (pt) | fluorometil-5,6-di-hidro-4h-[1,3]oxazinas, seus usos, e composição farmacêutica | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
| EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
| EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
| BR112013019955A2 (pt) | n-[3-(5-amino-3,3a,7,7a-tetra-hidro-1h-2,4-dioxa-6-aza-inden-7-il)-fenil]-amidas como inibidores de bace1 e/ou de bace2 | |
| BR112013031510A2 (pt) | [1,3]oxazinas | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
| BR112013021798A2 (pt) | 1,4 tiazepinaas/sulfonas como inibidores de bace1 e/ou bace2 | |
| BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
| EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
| BR112017022757A2 (pt) | derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap) | |
| BR112017015474A2 (pt) | inibidores de bace1 | |
| BR112016007430A2 (pt) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
| BR112016026814A8 (pt) | 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica | |
| BR112019000603A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| EA201400492A1 (ru) | Фармацевтические композиции, содержащие комбинацию основания абакавира и ламивудина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |